您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > SW106065
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
SW106065
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
SW106065图片
规格:98%
分子量:204.25
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
SW106065是恶性周围神经鞘瘤(MPNST)的凋亡(apoptosis)诱导剂。SW106065以EC50为1µM来抑制sMPNST细胞和其他模型中MPNST的ATP消耗。SW106065可用于MPNST的研究。
货号:ajcx31878
CAS:62289-81-0
分子式:C10H8N2OS
分子量:204.25
溶解度:DMSO: 100 mg/mL (489.60 mM)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

SW106065 is an apoptosis inducer in malignant peripheral nerve sheath tumors (MPNST). SW106065 inhibits ATP consumption of sMPNST and other models of MPNST with an EC50 of 1 µM. SW106065 can be used for MPNST research[1].

SW106065 (Compound 21, Cpd21) inhibits the human MPNST cell lines growth in a dose-dependent manner, and EC50 concentrations of 439 nM and 753.6 nM for S462 and SNF96.2 cells, respectively. SW106065 remains nontoxic to normally dividing Schwann cells or mouse embryonic fibroblasts[1].SW106065 (Cpd21; 0.25-5 µM; 24 hours; sMPNST cells) treatment shows a decreased percentage of cells in S phase, and a corresponding increased percentage in G1/G0 and G2/M[1]. SW106065 (Cpd21; 0.25-5 µM; 24 hours; sMPNST cells) treatment decreases the levels of cyclin A2, cyclin B1, cyclin D1, cyclin E, cdk4, and cdk6. And increases levels of cdkn1a and cdkn2a mRNA were observed in a dose-dependent manner.SW106065 (Cpd21; 0.25-5 µM; 24 hours; sMPNST cells) treatment decreases the levels of Cyclin D1 protein[1].SW106065 (Cpd21) treatment significant increase in the percentage of apoptotic cells[1]. Cell Cycle Analysis[1] Cell Line: sMPNST cells

SW106065 (Cpd21; 40 mg/kg; intraperitoneal injection; twice per day for 4 weeks) treatment can be delivered to mice in concentrations to sufficiently penetrate sMPNST tissue, and inhibit tumor development[1]. Animal Model: NCR-nu/nu female mice (6-7 week old) injected with MPNST cells[1]

[1]. Vincent Chau, et al. Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors. Cancer Res. 2014 Jan 15;74(2):586-97.